^
Association details:
| Biomarker: | BCL2 overexpression |
|---|---|
| Cancer: | Hodgkin Lymphoma |
| Drug: | Venclexta (venetoclax) (Bcl2 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Apoptotic regulator BCL-2 blockade as a potential therapy in classical Hodgkin Lymphoma
Published date:
01/06/2021
Excerpt:
cHL cell lines were treated with venetoclax alone....Patients with ≥60% BCL-2+ HRS-cells had a shorter disease-free survival (DFS) and overall survival (OS) (p = 0.002, p = 0.02 respectively).
DOI:
10.1016/j.lfs.2020.118979
Source:
Title:
Apoptotic regulator BCL-2 blockade as a potential therapy in classical Hodgkin Lymphoma
Published date:
01/06/2021
Excerpt:
cHL cell lines were treated with venetoclax alone or combined with vincristine or doxorubicin....Patients with ≥60% BCL-2+ HRS-cells had a shorter disease-free survival (DFS) and overall survival (OS) (p = 0.002, p = 0.02 respectively).
Secondary therapy:
pegylated liposomal doxorubicin; vincristine
DOI:
10.1016/j.lfs.2020.118979
